Latest court orders, judgments, and legal developments from Indian courts — AI-curated and summarized.
SEBI has amended the Mutual Funds Regulations, 2026, allowing mutual funds to engage in intraday borrowing to address timing mismatches, contingent upon adhering to conditions set by SEBI.
SEBI mandates that custodians will now be required to report and pay fees on a monthly basis, effective from October 1, 2026. This change is part of an ongoing effort to enhance compliance and oversight.
SEBI's recent notification updates the fee structure and registration requirements for Foreign Portfolio Investors (FPIs). Significant changes include revised remittance timelines and effective dates aligned with the amended 2019 Regulations.
The NCLAT ruled that the articles of association cannot override the eligibility requirements in the Companies Act for CFO appointments.
The Kerala High Court held that NCLT is empowered to accept additional pleadings in Section 7 IBC proceedings.
The Madhya Pradesh High Court ruled that a bona fide dispute regarding a debt prevents winding-up petitions under Section 433(e).
The NCLAT ruled that a continuing personal guarantee remains valid despite a guarantor's resignation or renewal of loan terms.
The CDSCO's notice on brand name extensions by pharmaceutical companies signals heightened regulatory oversight. Concerns around different formulations under the same brand prompt calls for comments from industry stakeholders.
The Punjab and Haryana High Court has ruled that a pre-cognizance hearing under the BNSS is not mandatory for complaints by the SFIO under the Companies Act. This decision clarifies procedural nuances in corporate investigations.
The Bombay High Court upheld a decision to refuse charitable registration to a trust offering legal and professional services, emphasizing the trust's intended operations.
The Bombay High Court quashed a customs demand for glucometers, reiterating the binding classification of such devices under Tariff Heading 9027.
CESTAT Chennai ruled that ELFA-based VIDAS diagnostic kits qualify for customs exemptions available under the ELISA kits notification, addressing procedural discrepancies in earlier rulings.